US welcomes import of mollusks from Spain and the Netherlands

Published Sep 25, 2020

Tridge summary

The US Food and Drug Administration (FDA) and the European Commission (EC) have made a breakthrough in allowing the sale of raw molluscan shellfish from the US and EU to consumers in the other region, marking the first time since 2010 that such imports will be permitted. The FDA's equivalence determination, published in the Federal Register, signifies that the EU's food safety control measures for raw bivalve molluscan shellfish, coupled with additional measures for export to the US, meet the same sanitary protection standards as the US. The agreement initially allows firms in Washington and Massachusetts to export to the EU, with other states to potentially follow. The FDA plans to evaluate and recognize other EU Member States as equivalent in the future, following a positive response to a proposed determination in 2018. A webinar for the shellfish industry is scheduled for October 2020 to provide more information.
Disclaimer:The above summary was generated by Tridge's proprietary AI model for informational purposes.

Original content

The US Food and Drug Administration (FDA) and the European Commission (EC) have taken important steps to open the market for the sale of raw molluscan shellfish, including oysters, clams, mussels and scallops, from both the United States and the European Union to their consumers. This was confirmed through the passing of the FDA’s equivalence determination, published earlier this week. Initially, certain firms in Washington and Massachusetts will have access to the EU market. US firms in other states soon will have an opportunity to be considered, using a streamlined process established by FDA and the EC. The FDA has announced its first-ever equivalence determination with a notice in the Federal Register – the daily journal of the US Government. The equivalence determination will enable Spain and the Netherlands to export raw bivalve molluscan shellfish to the United States. Specifically, FDA’s equivalence determination finds that the adoption and implementation by Spain and the ...

Would you like more in-depth insights?

Gain access to detailed market analysis tailored to your business needs.
By clicking “Accept Cookies,” I agree to provide cookies for statistical and personalized preference purposes. To learn more about our cookies, please read our Privacy Policy.